Onkologie. 2024:18(3):208-212 | DOI: 10.36290/xon.2024.039

Current treatment options of HER2+ metastatic colorectal carcinoma

Marián Liberko, Renata Soumarová
Onkologická klinika FNKV a 3. LF UK, Praha
3. lékařská fakulta Univerzity Karlovy, Praha

Metastatic colorectal cancer is currently still an incurable disease. However, thanks to advances in systemic therapy, the median survival of patients is increasing. The prolongation of overall survival is due to more personalized therapy according to the absence/presence of molecular alterations. One of these relatively newly investigated alterations and a novel target for therapy is HER2-positive metastatic colorectal cancer. The aim of this article is to provide a brief overview of current therapeutic options for this specific subset of metastatic disease.

Keywords: metastatic colorectal cancer, HER2 amplification, targeted therapy.

Accepted: June 18, 2024; Published: June 24, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Liberko M, Soumarová R. Current treatment options of HER2+ metastatic colorectal carcinoma. Onkologie. 2024;18(3):208-212. doi: 10.36290/xon.2024.039.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338. Go to original source... Go to PubMed...
    2. Dienstmann R, Salazar R, Tabernero J. Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. Am Soc Clin Oncol Educ Book. 2018;38:231-238. doi: 10.1200/EDBK_200929. PMID: 30231342. Go to original source... Go to PubMed...
    3. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics. 1989;4(3):362-366. doi: 10.1016/0888-7543(89)90343-1. PMID: 2565881. Go to original source... Go to PubMed...
    4. Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. Ann Oncol. 2001;12 Suppl 1:S9-13. doi: 10.1093/annonc/12.suppl_1.s9. PMID: 11521729. Go to original source... Go to PubMed...
    5. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469-6487. doi: 10.1038/sj.onc.1210477. Epub 2007 Apr 30. PMID: 17471238; PMCID: PMC3021475. Go to original source... Go to PubMed...
    6. Ahcene Djaballah S, Daniel F, Milani A, et al. S. HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target. Am Soc Clin Oncol Educ Book. 2022;42:1-14. doi: 10.1200/EDBK_351354. PMID: 35580290. Go to original source... Go to PubMed...
    7. Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017;8(49):86356-86368. doi: 10.18632/oncotarget.21169. PMID: 29156800; PMCID: PMC5689690. Go to original source... Go to PubMed...
    8. Ross JS, Fakih M, Ali SM, et al. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124(7):1358-1373. doi: 10.1002/cncr.31125. Epub 2018 Jan 16. PMID: 29338072; PMCID: PMC5900732. Go to original source... Go to PubMed...
    9. Cenaj O, Ligon AH, Hornick JL, et al. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma. Am J Clin Pathol. 2019;152(1):97-108. doi: 10.1093/ajcp/aqz031. PMID: 31115453. Go to original source... Go to PubMed...
    10. Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238(4):562-570. doi: 10.1002/path.4679. Epub 2016 Jan 29. PMID: 26690310; PMCID: PMC4785607. Go to original source... Go to PubMed...
    11. Tan RYC, Camat MD, Ng M, et al. HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients. Ann Oncol. 2018;29(7):1598-1599. doi: 10.1093/annonc/mdy156. PMID: 29868843. Go to original source... Go to PubMed...
    12. Chen PC, Yeh YM, Chu CT, et al. HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study. Eur J Cancer. 2023;181:62-69. doi: 10.1016/j.ejca.2022.12.019. Epub 2022 Dec 27. PMID: 36640475. Go to original source... Go to PubMed...
    13. Sartore-Bianchi A, Lonardi S, Aglietta M, et al. Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib. JAMA Oncol. 2020;6(6):927-929. doi: 10.1001/jamaoncol.2020.0571. PMID: 32324210; PMCID: PMC7180725. Go to original source... Go to PubMed...
    14. Valtorta E, Martino C, Sartore-Bianchi A,et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28(11):1481-1491. doi: 10.1038/modpathol.2015.98. Epub 2015 Oct 9. PMID: 26449765. Go to original source... Go to PubMed...
    15. Cercek A, Kimmie Ng, Strickler JH, et al. HER2 testing in colorectal cancer: Concordance analysis between breast and gastric scoring algorithms from the MOUNTAINEER trial. JCO. 2023;41:198-198. doi: 10.1200/JCO.2023.41.4_suppl.198. Go to original source...
    16. Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. Epub 2022 Oct 25. PMID: 36307056. Go to original source... Go to PubMed...
    17. Raghav K, Loree JM, Morris JS, et al. Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precis Oncol. 2019;3:1-13. doi: 10.1200/PO.18.00226. PMID: 35100667. Go to original source... Go to PubMed...
    18. Sartore-Bianchi A, Amatu A, Porcu L, et al. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. Oncologist. 2019; 24(10):1395-1402. doi: 10.1634/theoncologist. 2018-0785. Epub 2019 Apr 5. PMID: 30952821; PMCID: PMC6795149. Go to original source... Go to PubMed...
    19. Bekaii-Saab TS, Lach K, Hsu LI, et al. Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analy­sis of Clinical Outcomes. Oncologist. 2023;28(10):885-893. doi: 10.1093/oncolo/oyad200. PMID: 37463037; PMCID: PMC10546818. Go to original source... Go to PubMed...
    20. Laurent-Puig P, Balogoun R, Cayre, A, et al. ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8). Ann. Oncol. 2016;27(Suppl. S6):vi151. Go to original source...
    21. Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238(4):562-570. doi: 10.1002/path.4679. Epub 2016 Jan 29. PMID: 26690310; PMCID: PMC4785607. Go to original source... Go to PubMed...
    22. Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011; 1(6):508-523. doi: 10.1158/2159-8290.CD-11-0109. Epub 2011 Sep 2. PMID: 22586653. Go to original source... Go to PubMed...
    23. Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20. Erratum in: Lancet Oncol. 2016;17(10):e420. PMID: 27108243. Go to original source... Go to PubMed...
    24. Tosi F, Sartore-Bianchi A, Lonardi S, et al. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2020;19(4):256-262.e2. doi: 10.1016/j.clcc.2020.06.009. Epub 2020 Jun 27. PMID: 32919890. Go to original source... Go to PubMed...
    25. Sartore-Bianchi A, Lonardi S, Martino C, et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open. 2020;5(5):e000911. doi: 10.1136/esmoopen-2020-000911. PMID: 32988996; PMCID: PMC7523198. Go to original source... Go to PubMed...
    26. Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4):518-530. doi: 10.1016/S1470-2045(18)30904-5. Epub 2019 Mar 8. PMID: 30857956; PMCID: PMC6781620. Go to original source... Go to PubMed...
    27. Gupta R, Meric-Bernstam F, Rothe M, et al. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022;6:e2200306. doi: 10.1200/PO.22.00306. PMID: 36315917. Go to original source... Go to PubMed...
    28. Nakamura Y, Okamoto W, Kato T, et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med. 2021;27(11):1899-1903. doi: 10.1038/s41591-021-01553-w. Epub 2021 Nov 11. PMID: 34764486; PMCID: PMC8604726. Go to original source... Go to PubMed...
    29. Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24(5):496-508. doi: 10.1016/S1470-2045(23)00150-X. PMID: 37142372. Go to original source... Go to PubMed...
    30. Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22(6):779-789. doi: 10.1016/S1470-2045(21)00086-3. Epub 2021 May 4. PMID: 33961795. Go to original source... Go to PubMed...
    31. Yoshino T, Di Bartolomeo M, Raghav K, et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun. 2023;14(1):3332. doi: 10.1038/s41467-023-38032-4. PMID: 37286557; PMCID: PMC10247780. Go to original source... Go to PubMed...
    32. Raghav KPS, Siena S, Takashima A, et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. J Clin Oncol. 2023;41(suppl 16):3501. doi:10.1200/JCO.2023.41.16_suppl.3501. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.